STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This proposal, developed in the framework of the GIMEMA, will permit:
- to evaluate the activity and toxicity of imatinib in the treatment of Ph+ acute
lymphoblastic leukemia;
- to evaluate the molecular response to the treatment, and to monitor the molecular status
of remission in all cases achieving or not a molecular response.
The GIMEMA has activated a network to centralize all biological samples (bone marrow and
peripheral blood) at diagnosis from all new ALL patients. This will permit to identify, in
particular, Ph + and/or BCR/ABL + cases within 5 days from diagnosis, thus permitting to
treat these patients according to different programs on the basis of the presence of Ph
chromosome.